Repligen Co. (NASDAQ:RGEN) Stake Boosted by Point72 Asset Management L.P.

Point72 Asset Management L.P. grew its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 183.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 918,623 shares of the biotechnology company's stock after purchasing an additional 594,189 shares during the period. Point72 Asset Management L.P. owned about 1.64% of Repligen worth $132,227,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Signaturefd LLC increased its stake in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. purchased a new position in Repligen in the fourth quarter valued at $29,000. Itau Unibanco Holding S.A. acquired a new position in Repligen during the 4th quarter worth $40,000. UMB Bank n.a. raised its position in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its stake in shares of Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after buying an additional 129 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on RGEN. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research report on Tuesday, April 29th. Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, Royal Bank of Canada cut their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Insiders Place Their Bets

In related news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by company insiders.

Repligen Price Performance

Shares of NASDAQ RGEN traded up $1.14 during midday trading on Tuesday, hitting $127.33. The company had a trading volume of 239,852 shares, compared to its average volume of 752,100. The firm has a market capitalization of $7.15 billion, a price-to-earnings ratio of -249.66, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a twelve month low of $102.96 and a twelve month high of $182.52. The business has a 50-day simple moving average of $132.36 and a two-hundred day simple moving average of $145.11. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $0.28 EPS. Equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.